Purpose: Although immune checkpoint inhibitor-based perioperative therapy has become the standard for resectable stage IIIA-N2 non-small cell lung cancer (NSCLC), not all patients are eligible for this approach. This study evaluated long-term outcomes of histology-based induction chemoradiotherapy (CRT) followed by surgery.
Ishibashi et al. (Thu,) studied this question.